NASDAQ · CRSP
Healthcare · Biotechnology
$59.03
Up+$0.70 (+1.20%)
Updated Sep 23, 2026, 9:17 AM
SID Score
5.0/10
Composite research score
Smart Money
54/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CRSP closed at $59.03 after 20 trading sessions, down 3.07% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 22, 2026 | $58.73 | $60.72 | $57.64 | $59.03 | 2.08M |
| Sep 21, 2026 | $57.98 | $59.24 | $56.8666 | $58.33 | 1.81M |
| Sep 18, 2026 | $58.00 | $59.34 | $55.6343 | $56.56 | 3.38M |
| Sep 17, 2026 | $53.90 | $59.21 | $53.12 | $57.325 | 3M |
| Sep 16, 2026 | $52.16 | $53.67 | $51.83 | $52.21 | 2.67M |
| Sep 15, 2026 | $52.57 | $52.845 | $51.49 | $51.83 | 1.25M |
| Sep 14, 2026 | $51.33 | $53.80 | $51.33 | $52.96 | 1.53M |
| Sep 11, 2026 | $52.35 | $53.21 | $51.62 | $51.72 | 856.71K |
| Sep 10, 2026 | $52.50 | $52.625 | $51.72 | $52.26 | 1.26M |
| Sep 9, 2026 | $54.595 | $54.90 | $53.31 | $53.45 | 1.18M |
| Sep 8, 2026 | $54.45 | $55.10 | $52.78 | $54.78 | 1.39M |
| Sep 4, 2026 | $56.06 | $57.21 | $55.35 | $55.79 | 904.29K |
| Sep 3, 2026 | $57.50 | $57.80 | $55.7201 | $56.49 | 1.49M |
| Sep 2, 2026 | $57.13 | $58.9627 | $55.5919 | $56.92 | 911.12K |
| Sep 1, 2026 | $56.22 | $57.13 | $55.43 | $56.82 | 890.82K |
| Aug 31, 2026 | $56.55 | $57.49 | $56.20 | $56.98 | 1.39M |
| Aug 28, 2026 | $58.22 | $59.3699 | $57.10 | $57.72 | 1.39M |
| Aug 27, 2026 | $59.12 | $60.11 | $58.02 | $59.37 | 1.19M |
| Aug 26, 2026 | $60.18 | $60.39 | $58.06 | $59.23 | 959.93K |
| Aug 25, 2026 | $57.93 | $61.55 | $57.5103 | $60.90 | 2.08M |
The latest Smart Investors Daily articles mentioning CRSP.
CRSP research
Company profile and research snapshot.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 31, 2026 | Citizens | Market Outperform | — |
| Aug 31, 2026 | Needham | Buy | — |
| Aug 25, 2026 | Citizens | Market Outperform | — |
| Aug 4, 2026 | Citigroup | Buy | — |
| Jul 8, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 18, 2026
With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for investors without being a smooth ride.
Yahoo · Sep 17, 2026
The average brokerage recommendation (ABR) for CRISPR Therapeutics (CRSP) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Yahoo · Sep 16, 2026
CRISPR Therapeutics (CRSP) is drawing fresh attention as investors digest management’s recent comments on faster CASGEVY uptake and prepare for an earnings update that is expected to show higher revenue and a smaller loss. CRISPR Therapeutics has seen momentum cool recently, with the share price down 5.4% over the past week and 3.2% over the last month, while the 1-year total shareholder return has declined 15.3%. This follows a 3-year total shareholder return of 9.3% and a 5-year total...
Yahoo · Sep 15, 2026
CRISPR Therapeutics AG (CRSP) reached $51.8 at the closing of the latest trading day, reflecting a -2.19% change compared to its last close.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CRSP.
